Clinical Trial Update: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial evaluating Sandostatin LAR plus Axitinib versus placebo in patients with advanced well-differentiated non-pancreatic neuroendocrine carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Axitinib (Axitinib)
• Sandostatin LAR (octreotide)

Snippet

Sponsor: Grupo Espanol de Tumores Neuroendocrinos | Conditions: Neuroendocrine Tumors, Advanced Cancer | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2026-04-28